JP-1366: A novel and potent potassium-competitive acid blocker that is effective in the treatment of acid-related diseases

The global prevalence of GERD is substantially increasing each year, and GERD is a chronic disease that reduces the quality of life of patients. The efficacy of conventional drugs is diverse, and most require long-term or lifetime administration; thus, the development of more effective therapeutic agents is needed. Herein, a more effective treatment for GERD was tested. We investigated whether JP-1366 affected gastric H+/K+-ATPase activity and used the Na+/K+-ATPase assay to confirm the selectivity of H+/K+-ATPase inhibition. To clarify the mechanism of enzyme inhibition, JP-1366 and TAK-438 were analyzed by Lineweaver-Burk. Also, we investigated the effects of JP-1366 in various models involving reflux esophagitis. We found that JP-1366 mediates strong, selective, and dose-dependent inhibition of H+/K+-ATPase. We found that JP-1366 significantly suppressed gastric acid secretion in histamine-treated pylorus-ligated rats in a dose-dependent manner. Additionally, we confirmed that JP-1366 inhibited histamine-stimulated gastric acid secretion in the HPD model. JP-1366 exhibited a more than 2-fold higher inhibitory effect on esophageal injury than TAK-438 in GERD lesions and had a more potent inhibitory effect in indomethacin- or aspirin-induced gastric ulcer rat models than TAK-438. Additionally, JP-1366 inhibited gastric ulcers. These results support the possibility that JP-1366 is a good candidate drug for treating acid-related diseases.

Abstract 4485: JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model

PARP inhibitors have prolonged the survival of various cancer patients with homologous recombination (HR) deficiencies. However, most patients eternally acquire resistance. Many attempts have been made, but there are no clear strategies to overcome resistance. We evaluated the efficacy and mechanism of JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase1/2, in olaparib resistant breast and ovary preclinical cancer models. We established olaparib resistance models using mammalian cancer cell lines and patient-derived tumor xenografts (PDTXs). Two olaparib-resistant cells cell lines (BT474-OR/SNU251-OR) were established by exposing parent BRCA1/2 mutation carrying BT474 and SNU251 (breast and ovary cancer) to gradually increasing the concentration of olaparib for 8 months. An olaparib-resistant PDTX model [WJO-003(O2)], the parent BRCA1 mutation carrying ovary cancer PDTX was engrafted and treated with olaparib in 75mg/kg twice daily for 1 month and then 100mg/kg twice daily for 3 months. Using established olaparib resistance models, the anti-tumor efficacy of JPI-547 was compared with olaparib, niraparib, and talazoparib. IC50 of BT474-OR and SNU251-OR cell lines showed 5.5 and 6.7 fold increase compared to those of parent cell lines, respectively. While JPI-547 treatment in BT474-OR and SNU251-OR showed similar IC50 to the matching parent cells. In the PARPi-sensitive PDTX model, CPDX-013, JPI-547 inhibited tumor growth the greatest among other PARP inhibitors. Remarkably, 4 of 7 mice showed complete regression of the tumors. In the olaparib-resistant PDTX model, WJO-003(O2), JPI-547 inhibited tumor growth the most effectively compared to other PARP inhibitors (at day 60, the mean tumor volume: 2539, 1319, 871, 601, and 29 mm3 in control, niraparib, olaparib, talazoparib, and JPI-547, respectively; p<0.01). Since JPI-547 treated groups suppressed the tumor growth the most effectively both in olaparib-sensitive and resistant PDTX, to test whether JPI-547 is effective in prior PARPi-exposed tumor, we switched a PARPi to JPI-547 when most of PARPi treated tumors slowly retrieved the tumor growth. This subsequent treatment of JPI-547 completely suppressed the growth of tumor compared to a single other PARPi treated groups in both olaparib-sensitive and resistant models. The data suggest that JPI-547 efficiently inhibits growth of the tumor previously exposed to other PAPRi. JPI-547 treated tumors showed a decrease of RAD51 in comparison to other PARPi treated groups, which is likely mediated by inhibition of tankyrase 1/2 by JPI-547 and suppression of TNK1/2-MERIT40 complex. Then this suppression resulted in blockade of HR repair.JPI-547 showed promising efficacy in an olaparib-resistant preclinical model. JPI-547 merits further clinical development in the PARP inhibitor-resistant ovary and breast cancer.

Citation Format: Min Sil Kang, Nar Katuwal, Mithun Ghosh, Young kyu Jeong, Sa deok Hong, Sung Min Park, John Kim, Hyunju Cha, Banyoon Cheon, Seul-Gi Kim, Yong Wha Moon. JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4485.

Carbon Dots as an Effective Fluorescent Sensing Platform for Metal Ion Detection

Fluorescent carbon dots (CDs) including carbon quantum dots (CQDs) and graphene quantum dots (GQDs) have drawn great interest because of their low cost and low toxicity, and they represent a new class of carbon materials prepared by simple synthetic routes. In particular, the optical properties of CDs can be easily tuned by the surface passivation of the organic layer and functionalization of the CDs. Based on the advantages of these carbon materials, CQDs and GQDs have been applied in various fields as nanoplatforms for sensing, imaging, and delivery. In this review, we discuss several synthetic methods for preparing CQDs and GQDs, as well as their physical properties, and further discuss the progress in CD research with an emphasis on their application in heavy metal sensing.

TMTC1 and TMTC2 are novel endoplasmic reticulum tetratricopeptide repeat-containing adapter proteins involved in calcium homeostasis

The endoplasmic reticulum (ER) is organized in part by adapter proteins that nucleate the formation of large protein complexes. Tetratricopeptide repeats (TPR) are well studied protein structural motifs that support intermolecular protein-protein interactions. TMTC1 and TMTC2 were identified by an in silico search as TPR-containing proteins possessing N-terminal ER targeting signal sequences and multiple hydrophobic segments, suggestive of polytopic membrane proteins that are targeted to the secretory pathway. A variety of cell biological and biochemical assays was employed to demonstrate that TMTC1 and TMTC2 are both ER resident integral membrane proteins with multiple clusters of TPR domains oriented within the ER lumen. Proteomic analysis followed by co-immunoprecipitation verification found that both proteins associated with the ER calcium uptake pump SERCA2B, and TMTC2 also bound to the carbohydrate-binding chaperone calnexin. Live cell calcium measurements revealed that overexpression of either TMTC1 or TMTC2 caused a reduction of calcium released from the ER following stimulation, whereas the knockdown of TMTC1 or TMTC2 increased the stimulated calcium released. Together, these results implicate TMTC1 and TMTC2 as ER proteins involved in ER calcium homeostasis.

Ca2+ influx and the store-operated Ca2+ entry pathway undergo regulation during mouse oocyte maturation

Changes in Ca²⁺ homeostasis render oocytes competent to undergo [Ca²⁺]_i oscillations and activation. During mouse oocyte maturation Ca²⁺ influx and SOCE are down-regulated, whereas [Ca²⁺]_ER content increases. Bypassing the down-regulation of Ca²⁺ influx disturbs oocyte maturation.

In preparation for fertilization, mammalian oocytes undergo optimization of the mechanisms that regulate calcium homeostasis. Among these changes is the increase in the content of the Ca²⁺ stores ([Ca²⁺]_ER), a process that requires Ca²⁺ influx. Nevertheless, the mechanism(s) that mediates this influx remains obscure, although is known that [Ca²⁺]_ER can regulate Ca²⁺ influx via store-operated Ca²⁺ entry (SOCE). We find that during maturation, as [Ca²⁺]_ER increases, Ca²⁺ influx decreases. We demonstrate that mouse oocytes/eggs express the two molecular components of SOCE—stromal interaction molecule 1 (Stim1) and Orai1—and expression of human (h) Stim1 increases Ca²⁺ influx in a manner that recapitulates endogenous SOCE. We observe that the cellular distribution of hStim1 and hOrai1 during maturation undergoes sweeping changes that curtail their colocalization during the later stages of maturation. Coexpression of hStim1 and hOrai1 enhances influx throughout maturation but increases basal Ca²⁺ levels only in GV oocytes. Further, expression of a constitutive active form of hStim1 plus Orai1, which increases basal Ca²⁺ throughout maturation, disturbs resumption of meiosis. Taken together, our results demonstrate that Ca²⁺ influx and SOCE are regulated during maturation and that alteration of Ca²⁺ homeostasis undermines maturation in mouse oocytes.

Regulation of inositol 1,4,5-trisphosphate receptor function during mouse oocyte maturation

At the time of fertilization, an increase in the intracellular Ca(2+) concentration ([Ca(2+)](i)) underlies egg activation and initiation of development in all species studied to date. The inositol 1,4,5-trisphosphate receptor (IP(3)R1), which is mostly located in the endoplasmic reticulum (ER) mediates the majority of this Ca(2+) release. The sensitivity of IP(3)R1, that is, its Ca(2+) releasing capability, is increased during oocyte maturation so that the optimum [Ca(2+)](i) response concurs with fertilization, which in mammals occurs at metaphase of second meiosis. Multiple IP(3)R1 modifications affect its sensitivity, including phosphorylation, sub-cellular localization, and ER Ca(2+) concentration ([Ca(2+)](ER)). Here, we evaluated using mouse oocytes how each of these factors affected IP(3)R1 sensitivity. The capacity for IP(3)-induced Ca(2+) release markedly increased at the germinal vesicle breakdown stage, although oocytes only acquire the ability to initiate fertilization-like oscillations at later stages of maturation. The increase in IP(3)R1 sensitivity was underpinned by an increase in [Ca(2+)](ER) and receptor phosphorylation(s) but not by changes in IP(3)R1 cellular distribution, as inhibition of the former factors reduced Ca(2+) release, whereas inhibition of the latter had no impact. Therefore, the results suggest that the regulation of [Ca(2+)](ER) and IP(3)R1 phosphorylation during maturation enhance IP(3)R1 sensitivity rendering oocytes competent to initiate oscillations at the expected time of fertilization. The temporal discrepancy between the initiation of changes in IP(3)R1 sensitivity and acquisition of mature oscillatory capacity suggest that other mechanisms that regulate Ca(2+) homeostasis also shape the pattern of oscillations in mammalian eggs.

Species-specific differences in the activity and nuclear localization of murine and bovine phospholipase C zeta 1

Injection of mammalian sperm extracts or cRNA of the sperm-specific phospholipase C zeta 1 (PLCZ1) has been shown to trigger repetitive oscillations in the concentration of free calcium ([Ca(2+)](i)), leading to oocyte activation and embryo development in all mammals studied to date. While PLCZ1 has cross-species activity, it has also been observed that species-specific differences may exist in the frequency and pattern of the resulting [Ca(2+)](i) oscillations following PLCZ1 cRNA injection into oocytes of different species. Accordingly, we used a crossover design strategy to directly investigate the activity of murine and bovine PLCZ1 in both murine and bovine oocytes. In murine oocytes, injection of murine Plcz1 cRNA induced [Ca(2+)](i) oscillations at 10-fold lower concentrations than bovine PLCZ1, although in bovine oocytes bovine PLCZ1 was more effective than murine Plcz1 at inducing [Ca(2+)](i) oscillations. Investigation of ITPR1 (IP(3)R1) down-regulation in bovine oocytes by PLCZ1 cRNA also showed that bovine PLCZ1 was more active in homologous oocytes. To determine whether these PLCZs exhibited similar cellular distribution, Venus-tagged PLCZ1 cRNA was injected into oocytes, and PLCZ1 was overexpressed. Bovine PLCZ1 failed to accumulate in the pronucleus (PN) of bovine or murine zygotes, despite possessing a putative nuclear localization signal. Conversely, murine PLCZ1 accumulated in the PN of both murine and bovine zygotes. These results demonstrate that murine PLCZ1 and bovine PLCZ1 possess species-specific differences in activity and suggest potential differences in the mode of action of the protein between the two species. Variation in sperm PLCZ1 protein content among species, along with oocyte-specific differences in the localization and availability of PLCZ1 substrates, may further contribute to optimize the activation stimulus to enhance embryo development.